Vancomycin resistance in Staphylococcus aureus

Yale Journal of Biology and Medicine

Volumn 90, Issue 2, 2017, Pages 269-281

  McGuinness, Will A ^a   Malachowa, Natalia ^a   DeLeo, Frank R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antibiotic resistance; Staphylococcus aureus; Vancomycin; VISA; VRSA

Indexed keywords

BETA LACTAM ANTIBIOTIC; COLISTIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; METICILLIN; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DRUG TREATMENT FAILURE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VANCOMYCIN INTERMEDIATE RESISTANT STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; DRUG EFFECTS; GENETICS; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS;

HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 85021327304     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (141)

1. Classics in infectious diseases: “on abscesses”: Alexander Ogston (1844-1929). Rev Infect Dis. 1984;6(1):122–128.
2. Roberts S, Chambers S. Diagnosis and management of Staphylococcus aureus infections of the skin and soft tissue. Intern Med J. 2005;35(s2):S97-S105.
3. Mitchell DH, Howden BP. Diagnosis and management of Staphylococcus aureus bacteraemia. Intern Med J. 2005;35:S17-S24.
4. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis–Prospective Cohort Study. Arch Intern Med. 2009;169(5):463-73.
5. Murray R. Staphylococcus aureus infective endocarditis: diagnosis and management guidelines. Intern Med J. 2005;35(s2):S25-S44.
6. Lowy FD. Staphylococcus aureus Infections. N Engl J Med. 1998;339(8):520-32.
7. Dantes R, Mu Y, Belflower R, Aragon D, Dumyati G, Harrison LH, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med. 2013;173(21):1970-8.
8. de Kraker MEA, Jarlier V, Monen JCM, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clin Microbiol Infect. 2013;19(9):860-8.
9. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2014. cited 2017 Apr 21. Available from: http://www.cdc.gov/abcs/reports-findings/survreports/mrsa14.html
10. Sorrell TC, Packham DR, Shanker S, Foldes M, Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Medd. 1982;97(3):344-50.
11. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166(19):2138-44.
12. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997;350(9092):1670-3.
13. Howe RA, Bowker KE, Walsh TR, Feest TG, MacGowan AP. Vancomycin-resistant Staphylococcus aureus. Lancet. 1998;351(9102):602.
14. Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol. 2010;1:134.
15. Gill SR, Fouts DE, Archer GL, Mongodin EF, DeBoy RT, Ravel J, et al. Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain. J Bacteriol. 2005;187(7):2426-38.
16. Holden MT, Feil EJ, Lindsay JA, Peacock SJ, Day NP, Enright MC, et al. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc Natl Acad Sci U. S. A. 2004;101(26):9786-91.
17. Lindsay JA. Genomic variation and evolution of Staphylococcus aureus. Intern J Med Microbiol. 2010;300(2):98-103.
18. Musser JM, Kapur V. Clonal analysis of methicillin-resistant Staphylococcus aureus strains from intercontinental sources: association of the mec gene with divergent phylogenetic lineages implies dissemination by horizontal transfer and recombination. J Clin Microbiol. 1992;30(8):2058-63.
19. Plough HH. Penicillin resistance of Staphylococcus aureus and its clinical implications. Am J Clin Pathol. 1945;15(10):446-51.
20. Rammelkamp CH, Maxon T. Resistance of Staphylococcus aureus to the action of penicillin. Exp Biol Med. 1942;51(3):386-9.
21. Barber M, Rozwadowska-Dowzenko M. Infection by penicillin-resistant staphylococci. Lancet. 1948;252(6530):641-4.
22. Roundtree PM, Freeman B. Infections caused by a particular phage type of Staphylococcus aureus. Med J Aust. 1955;2(5):157-61.
23. Robinson DA, Kearns AM, Holmes A, Morrison D, Grundmann H, Edwards G, et al. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone. Lancet. 2005;365(9466):1256-8.
24. Olsen JE, Christensen H, Aarestrup FM. Diversity and evolution of blaZ from Staphylococcus aureus and coagulase-negative staphylococci. J Antimicrob Chemother. 2006;57(3):450-60.
25. Jevons MP. “Celbenin”-resistant Staphylococci. BMJ. 1961;1(5219):124-5.
26. Ayliffe G. The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 1997;24(Supplement 1):S74-S9.
27. Jarvis WR, Schlosser J, Chinn RY, Tweeten S, Jackson M. National prevalence of methicillin-resistant Staphylococcus aureus in inpatients at US health care facilities, 2006. Am J Infect Control. 2007;35(10):631-7.
28. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. 2007;13(12):1840.
29. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R, et al. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992–2003. Clin Infect Dis. 2006;42(3):389-91.
30. Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7(9):629-41.
31. Centers for Disease Control and Prevention (CDC). Four pediatric deaths from communityacquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep. 1999;48(32):707-10.
32. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA. 1998;279(8):593-8.
33. Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2000;44(6):1549-55.
34. Ubukata K, Nonoguchi R, Matsuhashi M, Konno M. Expression and inducibility in Staphylococcus aureus of the mecA gene, which encodes a methicillin-resistant S. aureus-specific penicillin-binding protein. J Bacteriol. 1989;171(5):2882-5.
35. Deurenberg RH, Stobberingh EE. The evolution of Staphylococcus aureus. Infect Genet Evol. 2008;8(6):747-63.
36. Jenkins TC, McCollister BD, Sharma R, McFann KK, Madinger NE, Barron M, et al. Epidemiology of healthcare-associated bloodstream infection caused by USA300 strains of methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Infect Control Hosp Epidemiol. 2009;30(3):233-41.
37. Seybold U, Halvosa JS, White N, Voris V, Ray SM, Blumberg HM. Emergence of and risk factors for methicillin-resistant Staphylococcus aureus of community origin in intensive care nurseries. Pediatrics. 2008;122(5):1039-46.
38. Liu C, Graber CJ, Karr M, Diep BA, Basuino L, Schwartz BS, et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004–2005. Clin Infect Dis. 2008;46(11):1637-46.
39. Rudkin JK, Edwards AM, Bowden MG, Brown EL, Pozzi C, Waters EM, et al. Methicillin resistance reduces the virulence of healthcare-associated methicillin-resistant Staphylococcus aureus by interfering with the agr quorum sensing system. J Infect Dis. 2012;205(5):798-806.
40. D'Agata EM, Webb GF, Horn MA, Moellering RC Jr, Ruan S. Modeling the invasion of community-acquired methicillin-resistant Staphylococcus aureus into hospitals. Clin Infect Dis. 2009 Feb 1;48(3):274-84.
41. Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42(Supplement 1):S5-S12.
42. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med. 2000;342(10):710-21.
43. Kaatz GW, Seo SM, Dorman NJ, Lerner SA. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis. 1990;162(1):103-8.
44. Manquat G, Croize J, Stahl J, Meyran M, Hirtz P, Micoud M. Failure of teicolpanin treatment associated with an increase in MIC during therapy of Staphylococus aureus septicaemia. J Antimicrob Chemother. 1992;29(6):731-2.
45. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348(14):1342-7.
46. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin--United States, 2002. MMWR Morb Mortal Wkly Rep. 2002;51(26):565.
47. Walters MS, Eggers P, Albrecht V, Travis T, Lonsway D, Hovan G, et al. Vancomycin-resistant Staphylococcus aureus-Delaware, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(37):1056.
48. Arthur M, Molinas C, Depardieu F, Courvalin P. Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol. 1993;175(1):117-27.
49. Périchon B, Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrobial Agents Chemother. 2009;53(11):4580-7.
50. Zhu W, Murray PR, Huskins WC, Jernigan JA, McDonald LC, Clark NC, et al. Dissemination of an Enterococcus Inc18-Like vanA plasmid associated with vancomycin-resistant Staphylococcus aureus. Antimicrobial Agents Chemother. 2010;54(10):4314-20.
51. Dmitriev BA, Toukach FV, Holst O, Rietschel E, Ehlers S. Tertiary structure of Staphylococcus aureus cell wall murein. J Bacteriol. 2004;186(21):7141-8.
52. Tomasz A. The staphylococcal cell wall. Gram-positive pathogens, Second Edition: American Society of Microbiology; 2006. p. 443-455.
53. Barna JC, Williams DH. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol. 1984;38(1):339-57.
54. Reynolds PE. Studies on the mode of action of vancomycin. Biochim Biophys Acta. 1961;52(2):403-5.
55. Bugg TD, Wright GD, Dutka-Malen S, Arthur M, Courvalin P, Walsh CT. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry. 1991;30(43):10408-15.
56. Hong HJ, Hutchings MI, Buttner MJ. Biotechnology and Biological Sciences Research Council, UK. Vancomycin resistance VanS/VanR two-component systems. Adv Exp Med Biol. 2008;631:200-13.
57. Reynolds PE, Depardieu F, Dutka-Malen S, Arthur M, Courvalin P. Glycopeptide resistance mediated by enterococcal transposon Tn 1546 requires production of VanX for hydrolysis of D-alanyl-D-alanine. Mol Microbiol. 1994;13(6):1065-70.
58. Gutmann L, Billot-Klein D, Al-Obeid S, Klare I, Francoual S, Collatz E, et al. Inducible carboxypeptidase activity in vancomycin-resistant enterococci. Antimicrobial Agents Chemother. 1992;36(1):77-80.
59. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997;40(1):135-6.
60. Jackson MA, Hicks RA. Vancomycin failure in staphylococcal endocarditis. Pediatr Infect Dis J. 1987;6(8):750-751.
61. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006;50(9):3039-47.
62. Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de Lencastre H, Richardson P, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U. S. A. 2007;104(22):9451-6.
63. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The Development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med. 1999;340(7):517-23.
64. Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23(1):99-139.
65. Roch M, Clair P, Renzoni A, Reverdy M-E, Dauwalder O, Bes M, et al. Exposure of Staphylococcus aureus to subinhibitory concentrations of β-Lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2014;58(9):5306-14.
66. Haaber J, Friberg C, McCreary M, Lin R, Cohen SN, Ingmer H. Reversible antibiotic tolerance induced in Staphylococcus aureus by concurrent drug exposure. mBio. 2015;6(1):e02268-14.
67. Boyle-Vavra S, Carey RB, Daum RS. Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. J Antimicrob Chemother. 2001;48(5):617-25.
68. Daum RS, Gupta S, Sabbagh R, Milewski WM. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J Infect Dis. 1992;166(5):1066-72.
69. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum R, Labischinski H, Hiramatsu K. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother. 1998;42(2):199-209.
70. Moreira B, Boyle-Vavra S, Daum RS. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1997;41(8):1788-93.
71. Boyle-Vavra S, Challapalli M, Daum RS. Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance. Antimicrob Agents Chemother. 2003;47(6):2036-9.
72. Boyle-Vavra S, Labischinski H, Ebert CC, Ehlert K, Daum RS. A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2001;45(1):280-7.
73. Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EM, et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol. 2003;41(1):5-14.
74. Renzoni A, Barras C, François P, Charbonnier Y, Huggler E, Garzoni C, et al. Transcriptomic and functional analysis of an autolysis-deficient, teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(9):3048-61.
75. Scherl A, François P, Charbonnier Y, Deshusses JM, Koessler T, Huyghe A, et al. Exploring glycopeptide-resistance in Staphylococcus aureus: a combined proteomics and transcriptomics approach for the identification of resistance-related markers. BMC Genomics. 2006;7(1):296.
76. Vaudaux P, Francois P, Berger-Bächi B, Lew DP. In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus. J Antimicrob Chemother. 2001;47(2):163-70.
77. Koehl JL, Muthaiyan A, Jayaswal RK, Ehlert K, Labischinski H, Wilkinson BJ. Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2004;48(10):3749-57.
78. McCallum N, Karauzum H, Getzmann R, Bischoff M, Majcherczyk P, Berger-Bächi B, et al. In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance. Antimicrob Agents Chemother. 2006;50(7):2352-60.
79. Muthaiyan A, Jayaswal RK, Wilkinson BJ. Intact mutS in laboratory-derived and clinical glycopeptide-intermediate Staphylococcus aureus strains. Antimicrob Agents Chemother. 2004;48(2):623-5.
80. Pfeltz RF, Singh VK, Schmidt JL, Batten MA, Baranyk CS, Nadakavukaren MJ, et al. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob Agents Chemother. 2000;44(2):294-303.
81. Sakoulas G, Eliopoulos GM, Moellering RC, Wennersten C, Venkataraman L, Novick RP, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother. 2002;46(5):1492-502.
82. Katayama Y, Sekine M, Hishinuma T, Aiba Y, Hiramatsu K. Complete reconstitution of the vancomycin-intermediate Staphylococcus aureus phenotype of strain Mu50 in vancomycin-susceptible S. aureus. Antimicrobial Agents Chemother. 2016;60(6):3730-42.
83. Meehl M, Herbert S, Götz F, Cheung A. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51(8):2679-89.
84. McEvoy CRE, Tsuji B, Gao W, Seemann T, Porter JL, Doig K, et al. Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of walKR expression. Antimicrob Agents Chemother. 2013;57(7):3240-9.
85. Cui L, Isii T, Fukuda M, Ochiai T, Neoh H-m, da Cunha Camargo ILB, et al. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54(12):5222-33.
86. Matsuo M, Hishinuma T, Katayama Y, Cui L, Kapi M, Hiramatsu K. Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA to-VISA phenotypic conversion of strain Mu3. Antimicrob Agents Chemother. 2011; 55(9):4188–4195.
87. Herbert S, Bera A, Nerz C, Kraus D, Peschel A, Goerke C, et al. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci. PLoS Pathog. 2007;3(7):e102.
88. Howden BP, Smith DJ, Mansell A, Johnson PD, Ward PB, Stinear TP, et al. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol. 2008;8(1):1.
89. Nishi H, Komatsuzawa H, Fujiwara T, McCallum N, Sugai M. Reduced content of lysyl-phosphatidylglycerol in the cytoplasmic membrane affects susceptibility to moenomycin, as well as vancomycin, gentamicin, and antimicrobial peptides, in Staphylococcus aureus. Antimicrob Agents Chemother. 2004;48(12):4800-7.
90. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Götz F. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem. 1999;274(13):8405-10.
91. Ruzin A, Severin A, Moghazeh SL, Etienne J, Bradford PA, Projan SJ, et al. Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus. Biochim Biophys Acta. 2003;1621(2):117-21.
92. Gardete S, Wu S, Gill S, Tomasz A. Role of VraSR in antibiotic resistance and antibiotic-induced stress response in Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(10):3424-34.
93. Howden BP, Stinear TP, Allen DL, Johnson PD, Ward PB, Davies JK. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52(10):3755-62.
94. Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K. Two‐component system VraSR positively modulates the regulation of cell‐wall biosynthesis pathway in Staphylococcus aureus. Mol Microbiol. 2003;49(3):807-21.
95. McAleese F, Wu SW, Sieradzki K, Dunman P, Murphy E, Projan S, et al. Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate-S. aureus-type resistance to vancomycin. J Bacteriol. 2006;188(3):1120-33.
96. Utaida S, Dunman P, Macapagal D, Murphy E, Projan S, Singh V, et al. Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiology. 2003;149(10):2719-32.
97. Nelson JL, Rice KC, Slater SR, Fox PM, Archer GL, Bayles KW, et al. Vancomycin-intermediate Staphylococcus aureus strains have impaired acetate catabolism: implications for polysaccharide intercellular adhesin synthesis and autolysis. Antimicrob Agents Chemother. 2007;51(2):616-22.
98. Vidaillac C, Gardete S, Tewhey R, Sakoulas G, Kaatz GW, Rose WE, et al. Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus. J Infect Dis. 2013; 208(1):67-74.
99. Berscheid A, François P, Strittmatter A, Gottschalk G, Schrenzel J, Sass P, et al. Generation of a vancomycin-intermediate Staphylococcus aureus (VISA) strain by two amino acid exchanges in VraS. J Antimicrob Chemother. 2014;69(12):3190-8.
100. Cui L, Iwamoto A, Lian J-Q, Neoh H-m, Maruyama T, Horikawa Y, et al. Novel mechanism of antibiotic resistance originating in vancomycin-Intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(2):428-38.
101. Pereira PM, Filipe SR, Tomasz A, Pinho MG. Fluorescence ratio imaging microscopy shows decreased access of vancomycin to cell wall synthetic sites in vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51(10):3627-33.
102. Gardete S, Kim C, Hartmann BM, Mwangi M, Roux CM, Dunman PM, et al. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLOS Pathogens. 2012;8(2):e1002505.
103. Boyle-Vavra S, Berke SK, Lee JC, Daum RS. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother. 2000;44(2):272-7.
104. Claeys KC, Lagnf AM, Hallesy JA, Compton MT, Gravelin AL, Davis SL, et al. Pneumonia caused by methicillin-resistant Staphylococcus aureus: does vancomycin heteroresistance matter? Antimicrob Agents Chemother. 2016;60(3):1708-16.
105. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997–2001. Clin Infect Dis. 2003;36(4):429-39.
106. Zhang S, Sun X, Chang W, Dai Y, Ma X. Systematic review and meta-analysis of the epidemiology of vancomycin-intermediate and heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. PLoS ONE. 2015;10(8):e0136082.
107. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard-Ninth Edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
108. Tenover FC, Moellering RC. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007;44(9):1208-15.
109. Van Hal S, Lodise T, Paterson D. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755-71.
110. Horne K, Howden BP, Grabsch EA, Graham M, Ward P, Xie S, et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother. 2009;53(8):3447-52.
111. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis. 2009;9(10):617-24.
112. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38(3):448-51.
113. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004;38(4):521-8.
114. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother. 2007;60(4):788-94.
115. Howe RA, Monk A, Wootton M, Walsh TR, Enright MC. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis. 2004;10(5):855-7.
116. Ortwine JK, Werth BJ, Sakoulas G, Rybak MJ. Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the “seesaw effect”: Taking advantage of the back door left open? Drug Resistance Updat. 2013;16(3–5):73-9.
117. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol. 1997;179(8):2557-66.
118. Barber KE, Ireland CE, Bukavyn N, Rybak MJ. Observation of “Seesaw Effect” with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infect Dis Ther. 2014;3(1):35-43.
119. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-e55.
120. Foucault M-L, Courvalin P, Grillot-Courvalin C. Fitness cost of VanA-Type vancomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(6):2354-9.
121. Limbago BM, Kallen AJ, Zhu W, Eggers P, McDougal LK, Albrecht VS. Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States. J Clin Microbiol. 2014;52(3):998-1002.
122. Rossi F, Diaz L, Wollam A, Panesso D, Zhou Y, Rincon S, et al. Transferable vancomycin resistance in a community-associated MRSA lineage. N Engl J Med. 2014;370(16):1524-31.
123. Kos VN, Desjardins CA, Griggs A, Cerqueira G, Van Tonder A, Holden MTG, et al. Comparative genomics of vancomycin-resistant Staphylococcus aureus strains and their positions within the clade most commonly associated with methicillin-resistant S. aureus hospital-acquired infection in the United States. mBio. 2012;3(3), 1.
124. Hafer C, Lin Y, Kornblum J, Lowy FD, Uhlemann A-C. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2012;56(11):5845-51.
125. Yoo JI, Kim JW, Kang GS, Kim HS, Yoo JS, Lee YS. Prevalence of amino acid changes in the yvqF, vraSR, graSR, and tcaRAB genes from vancomycin intermediate resistant Staphylococcus aureus. J Microbiol. 2013;51(2):160-5.
126. Matsuo M, Cui L, Kim J, Hiramatsu K. comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3. Antimicrob Agents Chemother. 2013;57(12):5843-5853.
127. Bhattacharyya D, Banerjee J, Bandyopadhyay S, Mondal B, Nanda PK, Samanta I, et al. First report on vancomycin-resistant Staphylococcus aureus in bovine and caprine milk. Microb Drug Resist. 2016;22(8):675-81.
128. Kwok GML, O'Donoghue MM, Doddangoudar VC, Ho J, Boost MV. Reduced vancomycin susceptibility in porcine ST9 MRSA isolates. Front Microbiol. 2013;4:316.
129. Moreno LZ, Dutra MC, Moreno M, Ferreira TSP, da Silva GFR, Matajira CEC, et al. Vancomycin-intermediate livestock-associated methicillin-resistant Staphylococcus aureus ST398/t9538 from swine in Brazil. Mem Inst Oswaldo Cruz. 2016;111(10):659-61.
130. Kwong JC, McCallum N, Sintchenko V, Howden BP. Whole genome sequencing in clinical and public health microbiology. Pathology. 2015;47(3):199-210.
131. Gargis AS, Kalman L, Lubin IM. Assuring the quality of next-generation sequencing in clinical microbiology and public health laboratories. J Clin Microbiol. 2016;54(12):2857-65.
132. Hasman H, Saputra D, Sicheritz-Ponten T, Lund O, Svendsen CA, Frimodt-Møller N, et al. Rapid whole-genome sequencing for detection and characterization of microorganisms directly from clinical samples. J Clin Microbiol. 2014;52(1):139-46.
133. Chan JZM, Pallen MJ, Oppenheim B, Constantinidou C. Genome sequencing in clinical microbiology. Nat Biotech. 2012;30(11):1068-71.
134. Lefterova MI, Suarez CJ, Banaei N, Pinsky BA. Next-generation sequencing for infectious disease diagnosis and management: a report of the association for molecular pathology. J Mol Diagnost. 2015;17(6):623-34.
135. Köser CU, Holden MTG, Ellington MJ, Cartwright EJP, Brown NM, Ogilvy-Stuart AL, et al. Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak. N Engl J Med. 2012;366(24):2267-75.
136. Chiu C-M, Lin F-M, Chang T-H, Huang W-C, Liang C, Yang T, et al. Clinical detection of human probiotics and human pathogenic bacteria by using a novel high-throughput platform based on next generation sequencing. J Clin Bioinforma. 2014;4(1):1.
137. Finan J, Archer GL, Pucci MJ, Climo MW. Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2001;45(11):3070-5.
138. Trotonda MP, Xiong YQ, Memmi G, Bayer AS, Cheung AL. Role of mgrA and sarA in methicillin-resistant Staphylococcus aureus autolysis and resistance to cell wall-active antibiotics. J Infect Dis. 2009;199(2):209-18.
139. Renzoni A, Andrey DO, Jousselin A, Barras C, Monod A, Vaudaux P, et al. Whole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureus. PLoS ONE. 2011;6(6):e21577.
140. Schulthess B, Meier S, Homerova D, Goerke C, Wolz C, Kormanec J, et al. Functional characterization of the σB-dependent yabJ-spoVG operon in Staphylococcus aureus: role in methicillin and glycopeptide resistance. Antimicrob Agents Chemother. 2009;53(5):1832-9.
141. Renzoni A, Kelley WL, Barras C, Monod A, Huggler E, François P, et al. Identification by genomic and genetic analysis of two new genes playing a key role in intermediate glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(3):903-11.